Notice of Change of AGM Venue

Verici Dx plc

("Verici Dx" or the "Company") 

Notice of Change of AGM Venue

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces a change in venue of its Annual General Meeting ('AGM'), which will now take place at Harwood Capital, 6 Stratton Street, Mayfair, W1J 8LD on 19 May 2021 at 12.00pm.

As previously announced, the Company is providing a facility for shareholders to join the AGM either online or telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Directors would request that shareholders register for the meeting and submit questions in advance, before 10.30 a.m. 17 May 2021.

To register for dial-in details and to submit any questions please contact Walbrook PR via email at [email protected] or call +44 (0)20 7933 8787 

No other details have changed.

Shareholders are reminded that due to the UK Government restrictions on public gatherings as a consequence of the COVID-19 pandemic, it will not be possible for shareholders to attend the AGM in person. The Board, with this in mind and in accordance with the Corporate Insolvency and Governance Act 2020, has therefore decided that the AGM will be held as a 'closed' meeting with the minimum number of Directors and officers who hold shares, present, to form the necessary quorum. Regrettably, other shareholders will not be permitted to attend the meeting in person.

Copies of the Annual Report and Accounts and Notice of AGM are available on the Company's website here:

https://vericidx.com/investors/documents-and-presentations/

Enquiries:

About Verici Dx plc www.vericidx.com

Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

About Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care-from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.